Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer.
Mitsiades, C S
Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. [electronic resource] - Expert opinion on investigational drugs Jun 2001 - 1099-115 p. digital
Publication Type: Journal Article; Review
1354-3784
10.1517/13543784.10.6.1099 doi
Androgen Antagonists--pharmacology
Androgen Receptor Antagonists
Androgens--metabolism
Animals
Bone Neoplasms--drug therapy
Cell Survival--drug effects
Humans
Insulin-Like Growth Factor I--metabolism
Male
Prostatic Neoplasms--drug therapy
Receptor, IGF Type 1--metabolism
Receptors, Androgen--metabolism
Signal Transduction--drug effects
Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. [electronic resource] - Expert opinion on investigational drugs Jun 2001 - 1099-115 p. digital
Publication Type: Journal Article; Review
1354-3784
10.1517/13543784.10.6.1099 doi
Androgen Antagonists--pharmacology
Androgen Receptor Antagonists
Androgens--metabolism
Animals
Bone Neoplasms--drug therapy
Cell Survival--drug effects
Humans
Insulin-Like Growth Factor I--metabolism
Male
Prostatic Neoplasms--drug therapy
Receptor, IGF Type 1--metabolism
Receptors, Androgen--metabolism
Signal Transduction--drug effects